In the present study, we report the development and in vitro characterization of novel tetravalent tetraspecific antibodies for simultaneous targeting of HER1, HER3, IGF1R and cMet on tumor cells with the potential to overcome resistance mechanisms mediated by compensatory signaling between different RTK signaling pathways. This evidence concerns the gene MET and neoplasm.